IM
IMPZY.US Implanet SA ADR
- Market cap
- USD 230M
- P/E
- -
- P/B
- 10.22x
- ROE
- -
- Dividend yield
- 0.21%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is IMPZY.US undervalued?
Graham numberThe Graham number of Implanet SA ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Implanet SA ADR fundamental analysis
No fundamental analysis for Implanet SA ADR yet.
Implanet SA ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Implanet SA ADR
Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-Jazz Screw systems for posterior fixation. It also provides an ultrasonic osteot…
Full company profileImplanet SA ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Implanet SA ADR annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.83M | 7.84M | 6.72M | 7.41M | 3.89M | 6.14M | 8.03M | 7.45M | 9.41M | 12.5M | 28.5M |
| Gross Profit | 3.07M | 3.16M | 2.94M | 3.46M | 1.59M | 2.74M | 3.91M | 3.33M | 4.10M | 6.90M | 17.0M |
| Operating Income | -6.88M | -5.78M | -5.16M | -3.61M | -3.43M | -4.42M | -3.97M | -6.39M | -4.89M | -3.93M | -7.47M |
| EBITDA | -5.63M | -5.15M | -4.33M | -2.16M | -3.11M | -2.70M | -2.73M | -5.08M | -3.82M | -2.91M | -4.85M |
| Net Income | -7.29M | -6.61M | -5.55M | -3.65M | -3.98M | -3.09M | -3.54M | -6.68M | -4.37M | -4.38M | -8.56M |
| EPS | -0.79 | -0.57 | -0.37 | -0.15 | -0.06 | -0.02 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 16.5M | 12.6M | 8.85M | 9.65M | 8.70M | 16.7M | 14.5M | 10.6M | 14.9M | 18.4M | 17.7M |
| Total Liabilities | 6.80M | 6.28M | 6.45M | 8.21M | 7.68M | 13.9M | 10.9M | 10.8M | 14.2M | 18.0M | 19.5M |
| Shareholders' Equity | 9.66M | 6.29M | 2.40M | 1.44M | 1.02M | 2.80M | 3.54M | -174K | 727K | 404K | -1.72M |
| Cash & Short-term Investments | 6.07M | 3.61M | 400K | 450K | 1.14M | 1.87M | 531K | 248K | 1.60M | 3.01M | 1.01M |
| Total Debt | 3.70M | 2.25M | 2.64M | 4.12M | 4.66M | 9.61M | 6.80M | 6.15M | 6.50M | 5.92M | 5.46M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.89M | -4.47M | -4.44M | -2.81M | -3.02M | -3.45M | -2.40M | -1.45M | -2.19M | -589K | -1.82M |
| Capital Expenditure | 513K | 380K | 322K | 154K | 223K | 392K | 568K | 718K | 486K | 1.56M | 2.63M |
| Free Cash Flow | -6.41M | -4.85M | -4.77M | -2.96M | -3.29M | -3.91M | -3.04M | -2.17M | -2.81M | -2.15M | -4.45M |
| Ratios | |||||||||||
| ROE | -75.4% | -105.2% | -231.0% | -253.8% | -389.0% | -110.1% | -100.0% | - | -600.6% | -1,084.7% | - |
| ROA | -44.3% | -52.6% | -62.7% | -37.8% | -45.7% | -18.5% | -24.5% | -62.8% | -29.3% | -23.8% | -48.3% |
| Net Profit Margin | -93.1% | -84.3% | -82.6% | -49.2% | -102.2% | -50.3% | -44.1% | -89.6% | -46.4% | -35.1% | -30.0% |
| Debt to Equity | 0.38x | 0.36x | 1.10x | 2.87x | 4.56x | 3.43x | 1.92x | - | 8.94x | 14.66x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Implanet SA ADR dividends
Implanet SA ADR has not paid dividends in the last 9 fiscal years.
Who owns Implanet SA ADR
Ownership data of Implanet SA ADR is not available yet.
Implanet SA ADR company profile
- Company name
- Implanet SA ADR
- Ticker
- IMPZY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 49
- Fiscal year end
- December
- Address
- Technopole Bordeaux Montesquieu, Martillac, France, 33650
- Phone
- 33 5 57 99 55 55
- Website
- implanet.com
About Implanet SA ADR
Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-Jazz Screw systems for posterior fixation. It also provides an ultrasonic osteotomy surgical system; and knee prostheses under the Madison name. The company exports its products. Implanet S.A. was founded in 2006 and is headquartered in Martillac, France.
Implanet SA ADR management
4- Mr. Ludovic LastennetCEO, Commercial Director & Director
- Mr. David DieumegardVice President of Financial
- Ms. Yvanna PeigneOperations Manager
- Mr. Benjamin LetienneVP of Marketing & International Sales and Director